Abstract
The chemokine granulocyte chemotactic protein (GCP)-2/CXCL6 promotes tumor growth as angiogenesis inducer and neutrophil chemoattractant. The neutralizing capacity and specificity of monoclonal mouse anti-murine (mu)GCP-2/CXCL6 antibodies were evidenced by granulocyte chemotaxis and signaling assays. The half-life of the non-antigenic antibody in the blood circulation was approximately 15 days. The titers remained constant upon weekly injection. Tumor growth and lymphogenic metastases of human melanoma over-expressing muGCP-2 were reduced in mice treated with anti-muGCP-2. Moreover, the drop in muGCP-2 antibody titer correlated with the melanoma tumor size. Taken together, we show that functional blocking of GCP-2 inhibits tumor growth and metastases.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacokinetics
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Neutralizing / immunology
-
Antibodies, Neutralizing / pharmacology*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects*
-
Chemokine CXCL6 / genetics
-
Chemokine CXCL6 / immunology*
-
Chemokine CXCL6 / metabolism
-
Chemotaxis, Leukocyte / drug effects
-
Female
-
Granulocytes / drug effects
-
Granulocytes / metabolism
-
Humans
-
Melanoma / genetics
-
Melanoma / pathology
-
Melanoma / prevention & control*
-
Melanoma, Experimental / genetics
-
Melanoma, Experimental / metabolism
-
Melanoma, Experimental / prevention & control
-
Mice
-
Mice, Inbred Strains
-
Mice, Nude
-
Neoplasm Metastasis
-
Xenograft Model Antitumor Assays
Substances
-
Antibodies, Monoclonal
-
Antibodies, Neutralizing
-
Chemokine CXCL6